Aspirin as a potential drug repurposing candidate targeting estrogen receptor alpha in breast cancer: a molecular dynamics and in-vitro study
D Kaur, C Choudhury, R Yadav, L Kumari… - Journal of …, 2024 - Taylor & Francis
Estrogen receptor alpha (ERα) is expressed by 70% of breast cancers (BCs). Any
deregulation in ERα signaling is crucial for the initiation and progression of BC. Because of …
deregulation in ERα signaling is crucial for the initiation and progression of BC. Because of …
Lasofoxifene treatment of aromatase-resistant ER+ cancer
BS Komm, GL Greene - US Patent 12,023,321, 2024 - Google Patents
US12023321B2 - Lasofoxifene treatment of aromatase-resistant ER+cancer - Google
Patents US12023321B2 - Lasofoxifene treatment of aromatase-resistant ER+cancer …
Patents US12023321B2 - Lasofoxifene treatment of aromatase-resistant ER+cancer …
Lasofoxifene treatment of breast cancer
K Andreano, CY Chang, DP McDonnell… - US Patent …, 2024 - Google Patents
The disclosure provides methods for treating estrogen receptor positive (ER") cancer in
women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof …
women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof …
Lasofoxifene treatment of breast cancer
K Andreano, CY Chang, DP McDonnell… - US Patent …, 2024 - Google Patents
Watson, NW et al.,“Venous and arterial thrombosis associated with abemaciclib therapy for
metastatic breast cancer,” Cancer, vol. 128, Iss. 17, Jun. 29, 2022, pp. 3224-3232 Andreano …
metastatic breast cancer,” Cancer, vol. 128, Iss. 17, Jun. 29, 2022, pp. 3224-3232 Andreano …